Medindia
Medindia LOGIN REGISTER
Advertisement

GBT Reports Fourth Quarter 2017 Results

Tuesday, March 20, 2018 General News
Advertisement
Organic growth accelerating and margins improving

MONTEVIDEO, Uruguay, March 19, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 4Q17 and full year of 2017.

Advertisement

HIGHLIGHTS

Gross revenues for 4Q17 grew 14% in constant currency, totaling BRL 271.6M.

Net revenues for 4Q17 increased by 17.8% in constant currency, totaling BRL 244.4M.
Advertisement

Gross profit up 14.4% in 4Q17, in constant currency, totaling BRL 140.3M. Gross margin of 57.4%.

Adjusted EBITDA grew 5.5% in constant currency vs. 4Q16, amounting to BRL 73.2M in 4Q17. 19.2% growth excluding from the base an insurance recovery decoupled from its underlying loss (in 2Q17)

Adjusted net income up 6.9% in nominal terms from 4Q16, reaching BRL 36.9M in 4Q17.

Net revenues for full year 2017 at 817.5M, with 14% organic growth (excluding exchange rate effects, short-term businesses, divestitures and acquisitions).

Adjusted EBITDA reached BRL 199.4M in 2017, up 23.9% in constant currency.

Gross margin for full year 2017 improved 3.8 pp when compared to 2016, reaching 53.8%. Adjusted EBITDA margin improved 2.5 pp, reaching 24.4%, in the same period.

Contacts:Melissa Angelini[email protected] +55 11 5090-5927

Cision View original content:http://www.prnewswire.com/news-releases/gbt-reports-fourth-quarter-2017-results-300616306.html

SOURCE Grupo Biotoscana

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close